NCT00787410View on ClinicalTrials.gov

An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Mesothelioma
Interventions
DRUG

ZD1839

250mg tablet, once daily, orally administered

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY